ENTX
Price
$2.74
Change
-$0.17 (-5.84%)
Updated
Nov 13 closing price
Capitalization
125.12M
133 days until earnings call
Intraday BUY SELL Signals
JSPR
Price
$1.60
Change
-$0.01 (-0.62%)
Updated
Nov 14, 12:24 PM (EDT)
Capitalization
44.77M
Intraday BUY SELL Signals
Interact to see
Advertisement

ENTX vs JSPR

Header iconENTX vs JSPR Comparison
Open Charts ENTX vs JSPRBanner chart's image
Entera Bio
Price$2.74
Change-$0.17 (-5.84%)
Volume$56.78K
Capitalization125.12M
Jasper Therapeutics
Price$1.60
Change-$0.01 (-0.62%)
Volume$100
Capitalization44.77M
ENTX vs JSPR Comparison Chart in %
ENTX
Daily Signal:
Gain/Loss:
JSPR
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ENTX vs. JSPR commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTX is a Hold and JSPR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (ENTX: $2.74 vs. JSPR: $1.61)
Brand notoriety: ENTX and JSPR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTX: 32% vs. JSPR: 117%
Market capitalization -- ENTX: $125.12M vs. JSPR: $44.77M
ENTX [@Biotechnology] is valued at $125.12M. JSPR’s [@Biotechnology] market capitalization is $44.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTX’s FA Score shows that 0 FA rating(s) are green whileJSPR’s FA Score has 1 green FA rating(s).

  • ENTX’s FA Score: 0 green, 5 red.
  • JSPR’s FA Score: 1 green, 4 red.
According to our system of comparison, JSPR is a better buy in the long-term than ENTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTX’s TA Score shows that 4 TA indicator(s) are bullish while JSPR’s TA Score has 5 bullish TA indicator(s).

  • ENTX’s TA Score: 4 bullish, 6 bearish.
  • JSPR’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, JSPR is a better buy in the short-term than ENTX.

Price Growth

ENTX (@Biotechnology) experienced а -11.90% price change this week, while JSPR (@Biotechnology) price change was -12.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.64%. For the same industry, the average monthly price growth was -3.56%, and the average quarterly price growth was +66.73%.

Reported Earning Dates

ENTX is expected to report earnings on Mar 27, 2026.

Industries' Descriptions

@Biotechnology (+3.64% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ENTX($125M) has a higher market cap than JSPR($44.8M). ENTX YTD gains are higher at: 29.245 vs. JSPR (-92.470). ENTX has higher annual earnings (EBITDA): -10.55M vs. JSPR (-92.73M). JSPR has more cash in the bank: 39.5M vs. ENTX (10.9M). ENTX has less debt than JSPR: ENTX (203K) vs JSPR (2.16M). ENTX has higher revenues than JSPR: ENTX (166K) vs JSPR (0).
ENTXJSPRENTX / JSPR
Capitalization125M44.8M279%
EBITDA-10.55M-92.73M11%
Gain YTD29.245-92.470-32%
P/E RatioN/AN/A-
Revenue166K0-
Total Cash10.9M39.5M28%
Total Debt203K2.16M9%
FUNDAMENTALS RATINGS
ENTX vs JSPR: Fundamental Ratings
ENTX
JSPR
OUTLOOK RATING
1..100
473
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
34
Fair valued
PROFIT vs RISK RATING
1..100
80100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
3895
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JSPR's Valuation (34) in the null industry is somewhat better than the same rating for ENTX (72) in the Pharmaceuticals Major industry. This means that JSPR’s stock grew somewhat faster than ENTX’s over the last 12 months.

ENTX's Profit vs Risk Rating (80) in the Pharmaceuticals Major industry is in the same range as JSPR (100) in the null industry. This means that ENTX’s stock grew similarly to JSPR’s over the last 12 months.

ENTX's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as JSPR (99) in the null industry. This means that ENTX’s stock grew similarly to JSPR’s over the last 12 months.

ENTX's Price Growth Rating (38) in the Pharmaceuticals Major industry is somewhat better than the same rating for JSPR (95) in the null industry. This means that ENTX’s stock grew somewhat faster than JSPR’s over the last 12 months.

JSPR's P/E Growth Rating (4) in the null industry is significantly better than the same rating for ENTX (100) in the Pharmaceuticals Major industry. This means that JSPR’s stock grew significantly faster than ENTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTXJSPR
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
66%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 8 days ago
80%
Bullish Trend 25 days ago
74%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 8 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
ENTX
Daily Signal:
Gain/Loss:
JSPR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AP2.170.26
+13.61%
Ampco-Pittsburgh Corp
BDULF0.56N/A
N/A
Bangkok Dusit Medical Services Public Co., Ltd.
CIMEF0.82N/A
N/A
CIMC Enric Holdings Ltd.
NTNOF0.60N/A
N/A
NORTHERN OCEAN LTD
CERS1.60-0.05
-3.03%
Cerus Corp

ENTX and

Correlation & Price change

A.I.dvisor tells us that ENTX and WVE have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ENTX and WVE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTX
1D Price
Change %
ENTX100%
-5.84%
WVE - ENTX
33%
Poorly correlated
-4.10%
JSPR - ENTX
32%
Poorly correlated
-9.04%
XENE - ENTX
32%
Poorly correlated
+0.91%
CGEM - ENTX
31%
Poorly correlated
-0.96%
OPORF - ENTX
31%
Poorly correlated
N/A
More

JSPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, JSPR has been loosely correlated with AUPH. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if JSPR jumps, then AUPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JSPR
1D Price
Change %
JSPR100%
-9.04%
AUPH - JSPR
44%
Loosely correlated
-2.06%
ETHZ - JSPR
38%
Loosely correlated
-4.88%
AVXL - JSPR
35%
Loosely correlated
-17.54%
DSGN - JSPR
34%
Loosely correlated
-7.23%
APGE - JSPR
34%
Loosely correlated
-0.21%
More